Table 2.
Fold changes of gene-expression differences in microarray comparing quadriceps muscles from prednisolone (P)-treated and untreated het mice conserved with either lisinopril plus spironolactone (LS) or eplerenone plus lisinopril (EL) versus untreated het controls (Un)
| Fold Change |
||||
|---|---|---|---|---|
| Gene Symbol | Full Gene Name | P/Un | LS/Un | EL/Un |
| Regulation of cytokine production/immune response | ||||
| Adora2b | Adenosine A2b receptor | −2.4 | X | −2.1 |
| Ccl9 | Chemokine (C-C motif) ligand 9 | −4.3 | X | −5.2 |
| Cd14 | CD14 antigen | −2.4 | −2.8 | −2.8 |
| Cd80 | CD80 antigen | −3.4 | −2.9 | −3.1 |
| Csf2rb | Colony stimulating factor 2 receptor, β, low-affinity (granulocyte-macrophage) | −3.5 | −3.8 | −3.5 |
| Csf2rb2 | Colony stimulating factor 2 receptor, β2, low-affinity (granulocyte-macrophage) | −3.0 | X | −2.6 |
| Fcgr3 | Fc receptor, IgG, low-affinity III | −2.6 | −2.2 | −2.2 |
| Il1b | Interleukin 1β | −42.1 | X | −40.3 |
| Il6 | Interleukin-6 | −3.6 | −3.9 | −2.9 |
| Klrb1b | Killer cell lectin-like receptor subfamily B member 1B | −2.3 | −2.3 | X |
| Nfkbia | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | −4.7 | −2.8 | −2.1 |
| Oas1a | 2′-5′ oligoadenylate synthetase 1A | −3.2 | −2 | X |
| Oas1g | 2′-5′ oligoadenylate synthetase 1G | −2.9 | −2 | X |
| Srgn | Serglycin | −2.6 | X | −2.1 |
| Thbs1 | Thrombospondin 1 | −10.5 | −6.2 | −6.8 |
| Tlr8 | Toll-like receptor 8 | −2.3 | −2.1 | X |
| Wfdc17 | WAP four-disulfide core domain 17 | −3.6 | −2.1 | −2.6 |
| Zfp36 | Zinc finger protein 36 | −5.2 | −4.7 | −3.5 |
| Regulation of transcription | ||||
| Arntl | Aryl hydrocarbon receptor nuclear translocator-like | 2.8 | −2.3 | X |
| Cebpd | CCAAT/enhancer binding protein (C/EBP), delta | −7.4 | −4.5 | X |
| Cited2 | Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 | 2.6 | X | 2.5* |
| Dbp | D site albumin promoter binding protein | −2.2 | 4.2 | 3.1 |
| Dmrt2 | Doublesex and mab-3 related transcription factor 2 | 2.1 | −2 | X |
| Fgfrl1 | Fibroblast growth factor receptor-like 1 | 2.3 | X | 2.1 |
| Id1 | Inhibitor of DNA binding 1 | −2.9 | X | −2.6 |
| Id2 | Inhibitor of DNA binding 2 | −3.4 | −2.4 | X |
| Litaf | LPS-induced TN factor | −3.0 | −2.4 | −2.3 |
| Mxd1 | MAX dimerization protein 1 | −3.2 | −2.3 | −2.6 |
| Npas2 | Neuronal PAS domain protein 2 | 2.5 | −2.2 | X |
| Nr4a3 | Nuclear receptor subfamily 4, group A, member 3 | −10.7 | −5.6 | −4 |
| Pyhin1 | Pyrin and HIN domain family, member 1 | −4.5 | −2 | X |
| Rcor3 | REST corepressor 3 | 2.2 | X | 2 |
| Ion-binding and transport | ||||
| Adamts1 | A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1 | −3.1 | −2.5 | −2.2 |
| F5 | Coagulation factor V | −3.2 | X | −2.2 |
| Apoptosis | ||||
| Casp8 | Caspase 8 | −2.1 | −3.4* | X |
| Alternative splicing | ||||
| Asb14 | Ankyrin repeat and SOCS box-containing 14 | 2.0 | 2.8* | 3.37* |
| Fgfrl1 | Fibroblast growth factor receptor-like 1 | 2.3 | X | 2.1 |
| Plaur | Plasminogen activator, urokinase receptor | −2.5 | −2.4 | −2.7 |
| Transmembrane | ||||
| Atp1b4 | ATPase, Na+/K+ transporting, beta 4 polypeptide | 3.6 | 2 | 2.6 |
| Fcgr4 | Fc receptor, IgG, low affinity IV | −4.2 | −2.3 | X |
| Ifitm1 | Interferon induced transmembrane protein 1 | −2.3 | −2.2 | −2.1 |
| Ifrd1 | Interferon-related developmental regulator 1 | −2.6 | X | −2.3 |
| Ms4a4a | Membrane-spanning 4-domains, subfamily A, member 4A | −3.3 | −2.7 | −2.8 |
| Pnpla3 | Patatin-like phospholipase domain containing 3 | 2.2 | 2.1 | X |
| Slc15a3 | Solute carrier family 15, member 3 | −2.0 | −2.2 | X |
| Sntb1 | Syntrophin, basic 1 | 2.3 | 2.5 | X |
| Tmem252 | Transmembrane protein 252 | −4.6 | −2.9 | −3 |
| Ugcg | UDP-glucose ceramide glucosyltransferase | −2.9 | X | −2.2 |
| Unknown or specific functions | ||||
| Dhrs7c | Dehydrogenase/reductase (SDR family) member 7C | 3.9 | X | 2.2 |
| Dusp5 | Dual-specificity phosphatase 5 | −2.6 | −2.5 | −2.3 |
| Gm4980 | Predicted gene 4980 | 2.5 | X | 2.1 |
| Gm6307 | Predicted gene 6307 | 2.6 | X | 2.5 |
| Hdc | Histidine decarboxylase | −7.7 | −6.6 | −6 |
| Irs2 | Insulin receptor substrate 2 | −2.5 | −2.4 | X |
| Lrrc30 | Leucine rich repeat containing 30 | 2.7 | 2.1 | X |
| Lrrc39 | Leucine rich repeat containing 39 | 2.3 | 2.2 | X |
| Prr33 | Proline rich 33 | 2.4 | X | 2 |
| Ptpn1 | Protein tyrosine phosphatase, nonreceptor type 1 | −2.1 | −2.4 | X |
| Sec14l5 | SEC14-like 5 (S. cerevisiae) | 2.3 | 2.7 | 2.1 |
| Synpo2l | Synaptopodin 2-like | 2.0 | 2.1 | X |
| Tfpi2 | Tissue factor pathway inhibitor 2 | −3.0 | −2.3 | −2.4 |
| Tnfaip6 | Tumor necrosis factor-α-induced protein 6 | −5.5 | −7 | X |
Genes were functionally clustered using the Functional Annotation clustering tool from the Database for Annotation, Visualization and Integrated Discovery (DAVID). Positive fold changes indicate gene expression was increased with treatment and vice versa. Bold X's represent a lack of a 2-fold gene-expression change in the LS or EL treatment groups. Values underlined and italicized highlight gene-expression changes going in the opposite direction with P versus LS or EL treatment.
*
Functionally conserved gene family members in LS or EL comparisons (Cited4, Casp4, and Asb15).